Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Surgical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-014-4072-0PMID 25192683PMCID PMC4505812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and clinical activity of combining systemic ipilimumab with isolated limb infusion in patients with in-transit melanoma.

  2014cited by this paper
• Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

  2014cited by this paper
• Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion

  2014cited by this paper
• Current management of advanced melanoma: a transformed landscape

  2014cited by this paper
• Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience

  2013cited by this paper
• CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

  2013cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity Melanoma

  2012cited by this paper
• Predicting disease progression after regional therapy for in-transit melanoma.

  2012cited by this paper
• A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities

  2012cited by this paper
• Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

  2011cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial

  2009cited by this paper
• Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis

  2009cited by this paper
• Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience

  2008cited by this paper
• Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.

  2006cited by this paper
• Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy

  2004cited by this paper
• Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy

  1995cited by this paper
• Results of regional isolated perfusion for locally inoperable melanoma of the limbs

  1994cited by this paper
• Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.

  1994cited by this paper
• A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma

  1985cited by this paper
• Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.

  1982cited by this paper

• Management of In-Transit Metastatic Melanoma.

  2026cites this paper
• A Simplified Classification System for In-Transit Melanoma Metastases

  2025cites this paper
• Intralesional and Infusional Updates for Metastatic Melanoma

  2024cites this paper
• The Diagnosis and Management of Cutaneous Metastases from Melanoma

  2023influential citation
• Great Debate: Limb Infusion for Melanoma: A Thing of the Past?

  2023cites this paper
• European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma.

  2023cites this paper
• Isolated Limb Infusion for Limb-Threatening, Unresectable Sarcoma: Past Progress, Current Applications, and Future Directions

  2023cites this paper
• Management of In-Transit Metastatic Melanoma

  2023cites this paper
• Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver

  2023cites this paper
• The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies

  2021cites this paper
• Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis

  2021cites this paper
• Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience

  2021cites this paper
• Local and regional therapy for primary and locally recurrent melanoma.

  2021cites this paper
• Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

  2020cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2020cites this paper
• Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.

  2020cites this paper
• ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma

  2020cites this paper
• Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia

  2020cites this paper
• Isolated Limb Infusion for Melanoma

  2020cites this paper
• First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?

  2019cites this paper
• Patients with in‐transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV‐10—A propensity score matched, single center study

  2019cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2019cites this paper
• Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice

  2019cites this paper
• Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma

  2019cites this paper
• BRAF status as a predictive factor for response in isolated limb perfusion

  2019influential citation
• Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

  2019cites this paper
• Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.

  2019cites this paper
• Isolated Limb Infusion for Melanoma

  2018cites this paper
• Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade

  2018cites this paper
• Management of Locally and Regionally Recurrent Melanoma

  2018cites this paper
• Minimally invasive isolated limb perfusion – technical details and initial outcome of a new treatment method for limb malignancies

  2018cites this paper
• Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

  2018cites this paper
• Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions

  2017cites this paper
• Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study

  2017cites this paper
• Australian Multicenter Study of Isolated Limb Infusion for Melanoma

  2016cites this paper
• Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma

  2016cites this paper
• The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options

  2015cites this paper
• Australian Multicenter Study of Isolated Limb Infusion for Melanoma

  2015cites this paper